(Reuters Health) - British citizens with HIV who live in Spain could face serious healthcare challenges in the event of a no-deal Brexit, potentially risking public health at large, researchers say.
PetMed Express Inc attributed the improvement in its quarterly profit margin to new supply contracts with manufacturers of animal drugs and said it expected the intense price war among online retailers of pet products to ease.
Alexion Pharmaceuticals Inc on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc in a deal initially valued at $930 million, as the company looks to retain its leadership in treating certain rare blood disorders.
UnitedHealth Group Inc on Tuesday provided an optimistic outlook for 2020 profit, saying it expected growth to be at least 13%, which outpaces current Wall Street estimates and sent its shares up as much as 8.6%.
Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.
Oct 9 Shares of Johnson & Johnson dipped 2% on
Wednesday after a jury awarded $8 billion in punitive damages to
a man who accused the drugmaker of failing to warn that young
men using its antipsychotic drug Risperdal could grow breasts.
(Reuters Health) - Nurses' productivity takes a hit when they become 'addicted' to using social media at work, a habit that distracts them from tasks at hand, a small study suggests.
(Reuters Health) - When a family member has celiac disease, Mayo Clinic researchers recommend parents, siblings and children also be tested, after a new study suggests first-degree relatives frequently have the condition, too - often without typical symptoms.
Sept 20 The U.S. Food and Drug Administration on
Friday approved an oral version of Novo Nordisk's
diabetes drug semaglutide, a boost for the Danish drugmaker
which hopes to transform the market by offering patients a
A U.S. Food and Drug Administration advisory panel on Friday recommended approving the first therapy for peanut allergies, which affect over 1.6 million children in the United States, despite raising concerns about the risk of severe allergic reactions it poses to young patients.